According to the complaint, the allegedly infringing products include all those that use nucleotides with a 3’-O-azidomethyl blocking group.
At the Advances in Genome Biology and Technology meeting this week, several MGI customers reported results from the DNBSeq-G400.
The deal will allow users of MGI's DNBSEQ sequencers to convert previously validated assays to the platform and access Sophia's analytics technology.
The DNBSeq Tx system, several of which are already up and running at the China National GeneBank, can churn out up to 100,000 human genomes per year.
BGI is planning to offer free trials of its MGI DNBSEQ-G400 sequencing system to key opinion leaders, a development Illumina is trying to stop.
The Shenzhen Mammoth Public Welfare Foundation, which BGI sponsors, has also raised funding to purchase PCR and automate sample preparation instruments.
The court dismissed BGI's counterclaim against Illumina for willful infringement of its patent but allowed the claim for induced infringement to proceed.
The new laboratory, which began trial operations this week, is designed to test 10,000 samples per day for the 2019-nCoV coronavirus.
A subsidiary of Curetis, a firm recently merged with OpGen, Ares will use BGI technology to sequence samples in Europe.
The DNBSEQ-T7 ultra-high-throughput sequencer, metagenomic sequencing kit for coronaviruses, and 2019-nCoV RT-qPCR kit have received authorization from China's NMPA.
A federal judge has ruled that drug companies, device manufacturers, and universities need to provide missing clinical data from hundreds of trials to a federal website, ScienceInsider reports.
A genetic analysis suggests red pandas might actually belong to two different species, New Scientist reports.
NPR reports that the US Centers for Disease Control and Prevention has fixed the problem with some of its SARS-CoV-2 testing kits.
In Nature this week: epigenetic factors that prevent healthy aging and more.